Corvus Pharmaceuticals, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$43.0M | -$27.5M | -$23.4M | -$32.6M | -$38.6M |
| Operating expenses | $43.0M | $27.5M | $23.4M | $32.6M | $38.6M |
| Cash from operations | -$32.8M | -$25.4M | -$23.9M | -$27.0M | -$36.7M |
| Capital expenditure | $174,000 | — | $34,000 | $269,000 | $5,000 |
| Free cash flow | -$33.0M | — | -$24.0M | -$27.3M | -$36.7M |
| Total assets | $71.1M | $68.9M | $45.6M | $68.2M | $109.5M |
| Total liabilities | $9.9M | $36.3M | $6.9M | $12.1M | $12.3M |
Shares outstanding 84.1M · Free float 74.5%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.